AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3354029 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 240 mg/day
Number of subjects: 29
Study 3354029 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 120 mg/day
Number of subjects: 29
Study 3354029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 31211416 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg of oral vitamin K2
Number of subjects: 95
Study 31211416 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg of oral vitamin K2
Number of subjects: 95
Study 31211416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 31211416 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vitamin K2 arms (200 μg and 400 μg)
Number of subjects: 95
Study 28878702 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigma-Stop serious game
Number of subjects: 552
Study 28878702 — intervention group
Group type: COMPARATOR
Intervention: Control group (unrelated video game)
Number of subjects: 552
Study 26835855 — intervention group
Group type: EXPERIMENTAL
Intervention: Group intervention I (IG I)
Number of subjects: 0
Study 26835855 — intervention group
Group type: EXPERIMENTAL
Intervention: Group intervention II (IG II)
Number of subjects: 0
Study 26835855 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 0
Study 22684211 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar extension traction in addition to hot packs and interferential therapy
Number of subjects: 64
Study 22684211 — intervention group
Group type: COMPARATOR
Intervention: Hot packs and interferential therapy
Number of subjects: 64
Study 21362731 — intervention group
Group type: EXPERIMENTAL
Intervention: NL-CPAP(2)
Number of subjects: 30
Study 21362731 — intervention group
Group type: COMPARATOR
Intervention: NL-HFPPV
Number of subjects: 30
Study 18434577 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated dentifrice
Number of subjects: 3
Study 18434577 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 3
Study 16527405 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% l‐menthol in ethanol
Number of subjects: 39
Study 16527405 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (control)
Number of subjects: 39
Study 14504920 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan 350 mg/m2 every 21 days (Group A)
Number of subjects: 120
Study 14504920 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan 175 mg/m2 days 1 and 10 every 21 days (Group B)
Number of subjects: 120
Study 12545845 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) treatment at a dose of 0.5 IU/(kg d) subcutaneously between days 3‐17 post‐burn
Number of subjects: 0
Study 12545845 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9177518 — intervention group
Group type: EXPERIMENTAL
Intervention: CLOtest
Number of subjects: 102
Study 9177518 — intervention group
Group type: COMPARATOR
Intervention: PyloriTek
Number of subjects: 102
Study 9177518 — intervention group
Group type: COMPARATOR
Intervention: PyloriTek (scored at 1 h)
Number of subjects: 102
Study 1524760 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 17
Study 1524760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 3912616 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + tamoxifen (Group CH)
Number of subjects: 81
Study 3912616 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only (Group C)
Number of subjects: 81
Study 30706309 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided TAP block
Number of subjects: 92
Study 30373835 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to images of a racially diverse environmental organization
Number of subjects: 0
Study 30373835 — intervention group
Group type: COMPARATOR
Intervention: Exposure to images of a nondiverse environmental organization
Number of subjects: 0
Study 26953999 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 17
Study 26953999 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 17
Study 25047263 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorotherapy with sodium fluoride (Elmex fluoride gel® 1.25%) administered once daily for 1 year
Number of subjects: 50
Study 25047263 — intervention group
Group type: COMPARATOR
Intervention: Control group (SG2) did not receive fluorotherapy
Number of subjects: 50
Study 22115977 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone beam CT imaging of the mandibular ramus and body in 10 patients (study group)
Number of subjects: 20
Study 22115977 — intervention group
Group type: COMPARATOR
Intervention: Routine presurgical imaging in 10 patients (control group)
Number of subjects: 20
Study 19674252 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial antioxidant compounds (EAC) plus sildenafil (100 mg)
Number of subjects: 53
Study 19674252 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil (100 mg) alone
Number of subjects: 53
Study 19674252 — intervention group
Group type: COMPARATOR
Intervention: EAC alone
Number of subjects: 53
Study 17652885 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering therapy (target LDL-C <70 mg/dl)
Number of subjects: 42
Study 17652885 — intervention group
Group type: COMPARATOR
Intervention: Moderate lipid-lowering therapy (target LDL-C <100 mg/dl)
Number of subjects: 42
Study 16146572 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory twitches using magnetic nerve stimulation
Number of subjects: 21
Study 16146572 — intervention group
Group type: COMPARATOR
Intervention: Expiratory twitches using magnetic nerve stimulation
Number of subjects: 21
Study 12116689 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum troponin I (Tnl) measurements at admission (Tnl-1) and after 8 hours (Tnl-2)
Number of subjects: 86
Study 10424833 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroQol EQ-5D
Number of subjects: 561
Study 10424833 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Utilities Index Mark II
Number of subjects: 561
Study 10424833 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroQol instrument
Number of subjects: 561
Study 7772628 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 100 mg twice daily intravenously from the day before operation until the third postoperative day
Number of subjects: 42
Study 7772628 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 42
Study 2108646 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital thrombolysis with Eminase
Number of subjects: 0
Study 2108646 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital thrombolysis
Number of subjects: 0
Study 2108646 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 7465140 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g cefamandole
Number of subjects: 100
Study 7465140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 7465140 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 100
Study 31809986 — intervention group
Group type: EXPERIMENTAL
Intervention: L2 penalized logistic regression
Number of subjects: 1328
Study 31809986 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial neural network
Number of subjects: 1328
Study 31809986 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest
Number of subjects: 1328
Study 31809986 — intervention group
Group type: EXPERIMENTAL
Intervention: AdaBoost
Number of subjects: 1328
Study 31809986 — intervention group
Group type: EXPERIMENTAL
Intervention: CatBoost
Number of subjects: 1328
Study 31809986 — intervention group
Group type: EXPERIMENTAL
Intervention: Support vector machine
Number of subjects: 1328
Study 31116169 — intervention group
Group type: EXPERIMENTAL
Intervention: Drill practice of key resuscitation phases
Number of subjects: 156
Study 31116169 — intervention group
Group type: COMPARATOR
Intervention: Scrimmage practice with reflective debriefs
Number of subjects: 156
Study 31116169 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Drill and Scrimmage)
Number of subjects: 156
Study 27846631 — intervention group
Group type: EXPERIMENTAL
Intervention: MLC601
Number of subjects: 880
Study 27846631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 880
Study 26277254 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates intervention (6 weeks)
Number of subjects: 97
Study 26277254 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy treatment alone (control group)
Number of subjects: 97
Study 23061430 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified remifentanil regimen
Number of subjects: 23
Study 23061430 — intervention group
Group type: COMPARATOR
Intervention: Classical remifentanil regimen
Number of subjects: 23
Study 21604490 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg lansoprazole IV infusion
Number of subjects: 12
Study 21604490 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole IV infusion
Number of subjects: 12
Study 21604490 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg lansoprazole IV infusion
Number of subjects: 12
Study 19526756 — intervention group
Group type: EXPERIMENTAL
Intervention: Shengmai Injection (SMI)
Number of subjects: 40
Study 16924025 — intervention group
Group type: EXPERIMENTAL
Intervention: GABRG2 mutation analysis
Number of subjects: 47
Study 16924025 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiologic studies
Number of subjects: 47
Study 15037271 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (0.05‐0.1 mg/kg per hour)
Number of subjects: 60
Study 15037271 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (0.25‐2.5 microg/kg per minute)
Number of subjects: 60
Study 11282569 — intervention group
Group type: EXPERIMENTAL
Intervention: Maharishi Vedic Vibration Technology (MVVT)
Number of subjects: 176
Study 11282569 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 176
Study 9390110 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (0.83 mg/hr for 7 days)
Number of subjects: 33
Study 9390110 — intervention group
Group type: EXPERIMENTAL
Intervention: Linsidomine (SIN-1)
Number of subjects: 33
Study 9390110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 8198935 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (DA) at 2.5 micrograms kg‐1 min‐1
Number of subjects: 17
Study 8198935 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 17
Study 3283777 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg pentoxifylline ('Trental') 3-times daily
Number of subjects: 76
Study 3283777 — intervention group
Group type: COMPARATOR
Intervention: 75 mg cinnarizine 3-times daily
Number of subjects: 76
Study 3283777 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg pentoxifylline ('Trental')
Number of subjects: 76
Study 3283777 — intervention group
Group type: COMPARATOR
Intervention: 75 mg cinnarizine
Number of subjects: 76
Study 30247751 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo beverages
Number of subjects: 240
Study 27164434 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir/3TC (ABC/3TC)
Number of subjects: 39
Study 27164434 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir/emtricitabine (TDF/FTC)
Number of subjects: 39
Study 25326140 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AG)
Number of subjects: 48
Study 25326140 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing exercises (BG)
Number of subjects: 48
Study 23565616 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral treatment with telbivudine
Number of subjects: 84
Study 23565616 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 84
Study 23565616 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 84
Study 20057999 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear Periodization Group (LPG, n = 14)
Number of subjects: 27
Study 20057999 — intervention group
Group type: EXPERIMENTAL
Intervention: Undulating Periodization Group (UPG, n = 13)
Number of subjects: 27
Study 17241768 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional voice therapy
Number of subjects: 184
Study 17241768 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 184
Study 17120738 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous moxifloxacin 400 mg once a day for 7 to 14 days
Number of subjects: 40
Study 17120738 — intervention group
Group type: COMPARATOR
Intervention: Cefoperazone 2.0 g twice a day and azithromycin 0.5 g once a day for 7 to 14 days
Number of subjects: 40
Study 17120738 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous moxifloxacin 400 mg once a day
Number of subjects: 40
Study 17120738 — intervention group
Group type: COMPARATOR
Intervention: Cefoperazone 2.0 g twice a day and azithromycin 0.5 g once a day
Number of subjects: 40
Study 17120738 — intervention group
Group type: EXPERIMENTAL
Intervention: Both moxifloxacin and cefoperazone plus azithromycin
Number of subjects: 40
Study 12838104 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-array surface electromyography in patients with acute low back pain (n = 13)
Number of subjects: 201
Study 12838104 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-array surface electromyography in patients with chronic low back pain (n = 25)
Number of subjects: 201
Study 12838104 — intervention group
Group type: COMPARATOR
Intervention: Large-array surface electromyography in healthy pain-free controls (n = 163)
Number of subjects: 201
Study 12838104 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-array surface electromyography in patients with acute low back pain (n = 3) whose pain resolved during the study
Number of subjects: 201
Study 10952121 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum/paclitaxel combination chemotherapy
Number of subjects: 0
Study 10952121 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/cyclophosphamide combination chemotherapy
Number of subjects: 0
Study 9085457 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 12
Study 9085457 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (0.15 g/kg and 0.45 g/kg)
Number of subjects: 12
Study 7524382 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with lidocaine (1 mg/kg) combined with moradol (0.005 mg/kg)
Number of subjects: 0
Study 7524382 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia with lidocaine (1 mg/kg) combined with morphine (0.01 mg/kg)
Number of subjects: 0
Study 3760659 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee-to-chest position
Number of subjects: 146
Study 3760659 — intervention group
Group type: COMPARATOR
Intervention: Dorsal position
Number of subjects: 146
Study 3760659 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid external sleeve added to catheter
Number of subjects: 146
Study 3760659 — intervention group
Group type: COMPARATOR
Intervention: Standard replacement method
Number of subjects: 146
Study 28243787 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal protein breakfast (milk)
Number of subjects: 28
Study 28243787 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant protein breakfast (oat, pea, potato)
Number of subjects: 28
Study 28243787 — intervention group
Group type: EXPERIMENTAL
Intervention: 50:50 mixture of animal and plant proteins
Number of subjects: 28
Study 28243787 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-rich meal
Number of subjects: 28
Study 27471879 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based intervention
Number of subjects: 184
Study 27471879 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 184
Study 24725238 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir for 12 weeks
Number of subjects: 440
Study 24725238 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir plus ribavirin for 12 weeks
Number of subjects: 440
Study 24725238 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir for 24 weeks
Number of subjects: 440
Study 24725238 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir plus ribavirin for 24 weeks
Number of subjects: 440
Study 22510600 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.2 Gy × 3 fractions
Number of subjects: 377
Study 22510600 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 Gy × 4 fractions
Number of subjects: 377
Study 20166163 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiant infrared (IR) light emitting diode (LED) (970 nm) pre-treatment for 15 minutes
Number of subjects: 10
Study 20166163 — intervention group
Group type: COMPARATOR
Intervention: Control side (no IR pre-treatment)
Number of subjects: 10
Study 20166163 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiant IR pre-treatment
Number of subjects: 10
Study 19065863 — intervention group
Group type: EXPERIMENTAL
Intervention: Monolingual participants judging dots moving left to right
Number of subjects: 0
Study 19065863 — intervention group
Group type: COMPARATOR
Intervention: Bilingual participants
Number of subjects: 0
Study 15851429 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation tubes
Number of subjects: 1234
Study 12423433 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin (25 mg daily or on alternate days)
Number of subjects: 23
Study 10509496 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (n=48)
Number of subjects: 80
Study 10509496 — intervention group
Group type: COMPARATOR
Intervention: Control (no nitric oxide, n=32)
Number of subjects: 80
Study 8606612 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 200
Study 8606612 — intervention group
Group type: COMPARATOR
Intervention: Small-incision cholecystectomy
Number of subjects: 200
Study 1726521 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid with UVB therapy
Number of subjects: 30
Study 1726521 — intervention group
Group type: COMPARATOR
Intervention: Indifferent ointment (control) with UVB therapy
Number of subjects: 30
Study 7034553 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight clothing
Number of subjects: 0
Study 7034553 — intervention group
Group type: COMPARATOR
Intervention: Loose fitted dresses
Number of subjects: 0
Study 31239010 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtheoretical model (TTM)‐based tailored behavioral intervention (TBI)
Number of subjects: 533
Study 31239010 — intervention group
Group type: COMPARATOR
Intervention: Non‐tailored intervention (NTI)
Number of subjects: 533
Study 31239010 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 533
Study 30046129 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus rhamnosus R0011 and Lactobacillus helveticus R0052)
Number of subjects: 70
Study 30046129 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Clavulanic Acid
Number of subjects: 70
Study 30046129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 27769263 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy (MuIS)
Number of subjects: 1101
Study 27769263 — intervention group
Group type: COMPARATOR
Intervention: Passive implementation strategy (PaIS)
Number of subjects: 1101
Study 25377958 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual diagnostic protocol
Number of subjects: 18
Study 25377958 — intervention group
Group type: COMPARATOR
Intervention: Traditional diagnostic protocol
Number of subjects: 18
Study 21988071 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra credit (social reward)
Number of subjects: 0
Study 21988071 — intervention group
Group type: COMPARATOR
Intervention: Equivalent cash reward (monetary reward)
Number of subjects: 0
Study 19845969 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 IU/day natural (RRR) alpha tocopherol for 20 weeks
Number of subjects: 20
Study 19845969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19845969 — intervention group
Group type: EXPERIMENTAL
Intervention: 100, 200, 400, 800 or 1600 IU/day of natural (RRR) alpha tocopherol
Number of subjects: 20
Study 17520464 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate foam 0.05%
Number of subjects: 24
Study 15154364 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenes‐korona rehabilitation complex
Number of subjects: 0
Study 12205733 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubeless group (n=56)
Number of subjects: 119
Study 12205733 — intervention group
Group type: COMPARATOR
Intervention: Intubated group (n=63)
Number of subjects: 119
Study 9814469 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) at doses of 40 mg, 20 mg, and 10 mg
Number of subjects: 46
Study 9814469 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous testosterone implant (100 mg)
Number of subjects: 46
Study 9814469 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal delivery system (TD1, TD2, TD3)
Number of subjects: 46
Study 9814469 — intervention group
Group type: COMPARATOR
Intervention: Placebo (study 2 control group)
Number of subjects: 46
Study 7662600 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (20 mg single oral dose)
Number of subjects: 24
Study 7662600 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) (20 mg single oral dose)
Number of subjects: 24
Study 7662600 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (2 x 20 mg/day for 8 days)
Number of subjects: 24
Study 7662600 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) (3 x 20 mg/day for 8 days)
Number of subjects: 24
Study 7662600 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) (2 x 20 mg/day for 8 days)
Number of subjects: 24
Study 7662600 — intervention group
Group type: COMPARATOR
Intervention: Nicorandil and Isosorbide dinitrate
Number of subjects: 24
Study 2727638 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg bacampicillin
Number of subjects: 8
Study 2727638 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg amoxycillin
Number of subjects: 8